NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HTG Molecular Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.66 +0.05 (+8.20 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$0.57Now: $0.66▼$0.6650-Day Range$0.61MA: $0.70▼$0.8352-Week Range$0.56Now: $0.66▼$3.24Volume3.66 million shsAverage Volume609,681 shsMarket Capitalization$38.31 millionP/E RatioN/ADividend YieldN/ABeta1.56 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HTGM Previous Symbol CUSIPN/A CIK1169987 Webhttp://www.htgmolecular.com/ Phone877-289-2615Debt Debt-to-Equity Ratio0.34 Current Ratio5.21 Quick Ratio5.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.50 million Price / Sales1.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book0.89Profitability EPS (Most Recent Fiscal Year)($0.60) Net Income$-16,450,000.00 Net Margins-76.97% Return on Equity-88.60% Return on Assets-40.99%Miscellaneous Employees107 Outstanding Shares58,042,000Market Cap$38.31 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive HTGM News and Ratings via Email Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HTGM Rates by TradingView HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions What is HTG Molecular Diagnostics' stock symbol? HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM." How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics Inc (NASDAQ:HTGM) issued its earnings results on Tuesday, November, 12th. The medical research company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The medical research company had revenue of $5.41 million for the quarter, compared to analyst estimates of $5.63 million. HTG Molecular Diagnostics had a negative net margin of 76.97% and a negative return on equity of 88.60%. View HTG Molecular Diagnostics' Earnings History. When is HTG Molecular Diagnostics' next earnings date? HTG Molecular Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for HTG Molecular Diagnostics. What guidance has HTG Molecular Diagnostics issued on next quarter's earnings? HTG Molecular Diagnostics issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $19.2-19.2 million, compared to the consensus revenue estimate of $19.38 million. What price target have analysts set for HTGM? 4 analysts have issued 12-month target prices for HTG Molecular Diagnostics' stock. Their forecasts range from $1.50 to $6.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $3.13 in the next year. This suggests a possible upside of 373.5% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics. What is the consensus analysts' recommendation for HTG Molecular Diagnostics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics. What are Wall Street analysts saying about HTG Molecular Diagnostics stock? Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock: 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (1/23/2020) 2. Canaccord Genuity analysts commented, "We were pleased to host newer HTG CEO John Lubniewski and CFO Conference last week in Boston. Our key takeaways: (1) HTG is making a bigger push to develop and launch novel diagnostic test launches in breast and lung cancer; (2) HTG is not getting any credit in its stock price for strong 80%+ Y/Y growth in its base RUO profiling business; and (3) HTG has taken adverse lumps" because they haven’t converted a CDx yet (yet they have over 70 active global pharma programs). We reiterate our BUY rating and trim our PT to $3, which we would be inclined to raise should HTG hit" on one of its pharma collaborations. EdgeSeq Breast Total Lung." (8/13/2019) 3. HC Wainwright analysts commented, "Our 12-month price target is based on an estimated market value of the firm at $237M. This includes an asset value at $247M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate, excluding $10M debt." (6/18/2019) 4. Cantor Fitzgerald analysts commented, "We reaffirm our OW rating and think HTG’s EdgeSeq offers an attractive workflow solution that addresses key challenges in many existing molecular profiling technologies on the market. We view RNA-based panels as well-positioned to capitalize on trends in biomarker development, including faster turnaround time, lower sample-volume requirement, and next-gen sequencing (NGS)- based testing. We think shares of HTG will be rewarded with consistent product and service revenue acceleration along with a demonstrated growing pipeline of exclusive revenue-generating PDPs." (2/20/2019) Has HTG Molecular Diagnostics been receiving favorable news coverage? Media stories about HTGM stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. HTG Molecular Diagnostics earned a news impact score of 1.2 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for HTG Molecular Diagnostics. Who are some of HTG Molecular Diagnostics' key competitors? Some companies that are related to HTG Molecular Diagnostics include Harvard Bioscience (HBIO), BioNano Genomics (BNGO), Arrayit (ARYC), Precipio (PRPO), Scientific Industries (SCND), Aethlon Medical (AEMD), Pressure Biosciences (PBIO) and PositiveID (PSID). What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Aurinia Pharmaceuticals (AUPH), Proteostasis Therapeutics (PTI), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), MEI Pharma (MEIP), Resonant (RESN), FleetMatics Group (FLTX), Gilead Sciences (GILD) and Synergy Pharmaceuticals (SGYP). Who are HTG Molecular Diagnostics' key executives? HTG Molecular Diagnostics' management team includes the folowing people: Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59) When did HTG Molecular Diagnostics IPO? (HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. How do I buy shares of HTG Molecular Diagnostics? Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is HTG Molecular Diagnostics' stock price today? One share of HTGM stock can currently be purchased for approximately $0.66. How big of a company is HTG Molecular Diagnostics? HTG Molecular Diagnostics has a market capitalization of $38.31 million and generates $21.50 million in revenue each year. The medical research company earns $-16,450,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe.View Additional Information About HTG Molecular Diagnostics. What is HTG Molecular Diagnostics' official website? The official website for HTG Molecular Diagnostics is http://www.htgmolecular.com/. How can I contact HTG Molecular Diagnostics? HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615. MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 292 (Vote Outperform)Underperform Votes: 252 (Vote Underperform)Total Votes: 544MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: Cost of Debt
